Exelixis Inc. (1EXEL)
MTA
Closed
Sep 28, 2026
Day's Range
50.9152 wk Range
29.27Overview - 1EXEL - Exelixis Inc.
Key Statistics
Valuation
Enterprise Value
10.57B
P/E (Trailing)
‪18.75‬
PEG Ratio
‪0.75‬
Price / Sales (TTM)
‪5.32‬
Price / Book
‪8.03‬
EV / EBITDA
‪11.75‬
Profitability
Gross Margin
‪96.71%‬
Profit Margin
‪35.33%‬
Operating Margin
‪39.51%‬
Return on Assets
‪23.97%‬
Return on Equity
‪44.39%‬
Ownership
Shares Outstanding
248.88M
Float
213.60M
Held by Insiders
‪1.84%‬
Held by Institutions
‪106.88%‬
Price stats
Beta
‪0.42‬
50-Day Avg
‪47.87‬
200-Day Avg
‪41.79‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 1EXEL - Exelixis Inc.
Peers - 1EXEL - Exelixis Inc.
Peer Comparison
Compared with companies in Biotechnology listed on MTA.
- 1EXELMTAExelixis Inc.10.56BMarket Cap+31.84%52-week change18.76P/E (Trailing)‪35.33%‬Profit Margin
- 1VRTXMTAVertex Pharmaceuticals Incorporated Common Stock107.27BMarket Cap+27.72%52-week change30.40P/E (Trailing)‪34.99%‬Profit Margin
- 1REGNMTARegeneron Pharmaceuticals, Inc.73.52BMarket Cap+30.66%52-week change19.47P/E (Trailing)‪27.86%‬Profit Margin
- 1ALNYMTAAlnylam Pharmaceuticals, Inc.45.81BMarket Cap-73.35%52-week change43.84P/E (Trailing)‪16.12%‬Profit Margin
- 1INSMMTAInsmed Incorporated30.28BMarket Cap-19.46%52-week change-16.17P/E (Trailing)‪-76.94%‬Profit Margin
- 1CGMTAThe Carlyle Group Inc.18.64BMarket Cap-40.10%52-week change42.38P/E (Trailing)‪13.01%‬Profit Margin
- 1INCYMTAIncyte Corp.17.89BMarket Cap+32.92%52-week change15.77P/E (Trailing)‪27.70%‬Profit Margin
Profile Summary - 1EXEL - Exelixis Inc.
About
Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
